arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Xeris Biopharma Holdings, Inc.

XERS
$13.10 ▲ +2.63 (+25.19%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
51
Health
Fair
Bearish
auto_awesome

Analytical Summary

Xeris Biopharma Holdings, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $2.3B
Dividend Yield —
Revenue Growth 28.7% ↘
Op. Margin 5.6% ↘
ROIC 1.7% ↘
FCF / Share $0.05 ↘
Trailing P/E —
Price / Book —
FCF Yield 0.4%
Debt / Equity -25.95
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$92.10M
↑ +28.7% —
Net Income Profit after all expenses
$2.23M
— 0.0% —
Operating Margin Operating profit as % of sales
5.6%
↓ -41.0% 53th
FCF / Share Free cash flow per share
$0.05
↓ -17.4% —
Long-Term Debt Long-term obligations
$252.59M
↑ +14.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
49
Returns
52
Financial Health ↑
28
Cash Quality ↑
100

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters